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Objective: Approximately 10–40% of rectal patients have a complete response (CR) to 
neoadjuvant chemoradiation (CRT), and these patients have improved survival. Thus, 
non-operative management (“watch-and-wait” approach) may be an option for select 
patients. We aimed to identify clinical predictors of CR following CRT.
Methods: Patients treated with definitive CRT for T3–T4, locally unresectable T1–T2, 
low-lying T2, and/or node-positive rectal cancer from August 2004 to February 2015 
were retrospectively reviewed. Most patients were treated with 50.4 Gy radiation and 
concurrent 5-fluoruracil or capecitabine. Patients were considered to have a CR if surgi-
cal pathology revealed ypT0N0M0 (operative management), or if they had no evidence of 
residual disease on clinical and radiographic assessment (non-operative management). 
Statistical analysis was carried out to determine predictors of CR and long-term outcomes.
results: Complete records were available on 138 patients. The median follow-up was 
24.5 months. Thirty-six patients (26.3%) achieved a CR; 30/123 operatively managed 
patients (24.5%) and 6/15 (40%) non-operatively managed patients. None of the 10 
patients with mucinous adenocarcinoma achieved a CR. Carcinoembryonic antigen 
(CEA) ≥5 μg/L at diagnosis (OR 0.190, 95% CI 0.037–0.971, p = 0.046), tumor size 
≥3 cm (OR 0.123, 95% CI 0.020–0.745, p = 0.023), distance of tumor from the anal 
verge ≥3 cm (OR 0.091, 95% CI 0.013–0.613, p = 0.014), clinically node-positive dis-
ease at diagnosis (OR 0.201, 95% CI 0.045–0.895, p = 0.035), and interval from CRT to 
surgery ≥8 weeks (OR 5.267, 95% CI 1.068–25.961, p = 0.041) were independent pre-
dictors of CR. The CR group had longer 3-year distant metastasis-free survival (DMFS) 
(93.7 vs. 63.7%, p =  0.016) and 3-year disease-free survival (DFS) (91.1 vs. 67.8%, 
p = 0.038). Three-year locoregional control (LRC) (96.6 vs. 81.3%, p = 0.103) and overall 
survival (97.2 vs. 87.5%, p = 0.125) were higher in the CR group but this did not achieve 
statistical significance. CR was not an independent predictor of LRC, DMFS, or DFS.
conclusion: CEA at diagnosis, tumor size, tumor distance from the anal verge, node 
positivity at diagnosis, and interval from CRT to surgery were predictors of CR. These 
clinical variables may offer insight into patient selection and timing of treatment response 
evaluation in the watch-and-wait approach.
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inTrODUcTiOn
The standard treatment of locally advanced rectal cancer consists 
of chemoradiation (CRT), followed by total mesorectal excision 
(TME) 4–8 weeks later. Interestingly, in the German CAO/ARO/
AIO-94 randomized phase III trial that established the superiority of 
preoperative CRT over postoperative CRT, 9% of patients achieved 
a pathologic complete response (pCR), defined as ypT0N0M0, 
following CRT. Other studies have reported a pCR rates ranging 
from ~10 to 40% (1–5). Further, Maas et  al. demonstrated that 
achievement of a pCR is associated with an improved outcome (2).
These findings raised interest in the possibility of a non-
operative treatment strategy, the “watch-and-wait” approach, 
for rectal cancer. Significant morbidity is associated with TME, 
including postoperative complications, creation of a definitive 
stoma, urinary and fecal incontinence, and sexual dysfunction. 
With the watch-and-wait approach, patients achieving a clinical 
complete response (cCR) have no immediate surgery, but instead 
are followed closely clinically and radiographically (6). Recent 
studies have reported rectal preservation rates of up to 78% and 
similar survival to patients treated operatively (7–10).
However, challenges remain in identifying which patients 
would benefit most from the watch-and-wait approach. Neither 
digital rectal examination (DRE), nor endoscopy, nor imaging 
is a perfect predictor of pCR (11–15). Thus, more accurate tests 
are needed in order to offer non-operative management to all 
patients who may benefit. Several studies have examined predic-
tors of complete response (CR); however, few have assessed how 
radiotherapy (RT) treatment parameters affect response to CRT 
and most do not correlate predictors with long-term outcomes. 
Thus, the aim of this study was to determine clinical or pathologic 
factors that are prognostic of achievement of a CR as well as long-
term oncologic outcomes following CRT for rectal cancer.
MaTerials anD MeThODs
study sites and Patient inclusion criteria
We conducted a chart review on all patients who had received 
CRT for rectal adenocarcinoma at the NYU Department of 
Radiation Oncology between August 2004 and February 2015. 
Patients with T3–T4, locally unresectable T1–T2, low-lying T2, 
and/or node-positive rectal cancer were included in this study. 
Patients were excluded if they had stage IV disease at the start 
of treatment, if they were referred for palliative RT, or if pathol-
ogy was not consistent with adenocarcinoma. Ten patients were 
excluded due to insufficient treatment data. We performed a 
retrospective analysis of the remaining 138 patients.
This study was approved by the New York University School 
of Medicine Institutional Review Board. Consent was waived as it 
was deemed that there was no more than minimal risk to research 
participants, the rights and welfare of the participants were not 
adversely affected, and the research could not be practicably 
conducted without a waiver.
Diagnosis and Treatment
Patients were clinically staged with colonoscopy with biopsy, 
endoscopic ultrasonography ± pelvic MRI, and chest/abdomen/
pelvis CT. External beam RT was delivered as either three-
dimensional RT or intensity modulated RT with continuous 
standard fractionation. The pelvis was treated to a dose of 
45 Gy, and gross disease received an additional dose of 5.4 Gy. 
All patients were treated in 1.8 Gy fractions. Most patients were 
treated concurrently with either continuous infusion 5-fluorura-
cil (5-FU) 225 mg/m2 over 24 h for 7 days/week or capecitabine 
825 mg/m2 twice a day for 5 days/week. A minority of patient 
received an oxaliplatin-containing regimen with either 5-FU or 
capecitabine.
Prior to February 2014, patients underwent either low 
anterior resection (LAR) or abdominoperineal resection (APR) 
5–12 weeks following neoadjuvant CRT. Patients who were not 
operative candidates or who preferred to not undergo surgery 
were followed per institutional routine.
After February 2014, patients with tumors assessable by DRE 
were managed per a formal watch-and-wait clinical protocol. 
Tumor response was assessed 10  weeks from the completion 
of RT with physical exam and DRE performed by the surgeon, 
flexible sigmoidoscopy, MRI ± PET/CT, and carcinoembryonic 
antigen (CEA) level. A cCR was defined as absence of residual 
tumor, ulceration, or rectal wall irregularity on both clinical 
and radiologic assessment. Radiologic features of cCR included 
presence of residual low-signal intensity and absence of restric-
tion to diffusion on MRI, or absence of residual FDG avidity 
in the rectal wall on PET/CT. Determination of cCR was made 
by a multidisciplinary tumor board, which reviewed the above 
clinical factors and imaging. Patients who did not achieve a cCR 
underwent LAR or APR 5–12 weeks following neoadjuvant CRT. 
Patients achieving a cCR were followed with physical exam and 
DRE, CEA level, and flexible sigmoidoscopy every 2 months in 
year 1, every 3 months in year 2, every 6 months in years 3–5, and 
yearly thereafter. Radiologic assessment consisted of chest/abdo-
men/pelvic CT and MRI ± PET/CT every 6 months in years 1–2 
and yearly thereafter. Patients who developed a local recurrence 
were offered standard TME surgery.
One hundred and twenty-two patients were treated prior 
to February 2014 and 16 patients were treated after. For all 
patients undergoing operative management, pCR was defined as 
ypT0N0M0.
Data
Data were collected on patient age at diagnosis, gender, histology, 
clinical stage at presentation, neutrophil and lymphocyte count 
at diagnosis and after CRT, and CEA level at diagnosis. Date of 
pathologic diagnosis, dates of RT, RT dose, presence of unplanned 
RT breaks, chemotherapy regimens, surgery date, surgical proce-
dure, and pathologic findings at surgery were recorded.
statistical analysis
Outcome measures were achievement of either pCR (operative 
management) or cCR (non-operative management) (“CR”), 
locoregional control (LRC), distant metastasis-free survival 
(DMFS), disease-free survival (DFS), and overall survival (OS). 
LRC was defined as the interval from the end of RT to local or 
regional failure or most recent follow-up. DMFS was defined as 
the interval from the end of RT to distant failure or most recent 
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follow-up. DFS was defined as the interval from the end of RT to 
the occurrence of local, regional, or distant failure, death, or most 
recent follow-up. OS was defined as the interval from the end of 
RT to the time of death by any cause or most recent follow-up.
Clinical and pathologic variables were compared between the 
CR and no CR groups using Student’s t-test to compare means 
and χ2 test to compare frequency. Univariable and multivariable 
binary logistic regression was used to assess predictors of CR. 
Survival curves for LRC, DMFS, DFS, and OS were created using 
the Kaplan–Meier method and compared with the log-rank 
test. Univariable and multivariable Cox proportional hazards 
regression was used to assess for predictors of LRC, DMFS, and 
DFS. CEA ≥5 μg/L at diagnosis was used as a cut-off as this is 
considered the normal value for smokers. Cut-off values for other 
continuous data were determined by the point on the receiver 
operator curve that maximized sensitivity and specificity. Patients 
who did not achieve a cCR and did not undergo surgery were 
excluded from the survival analysis. For all regression analyses, 
variables that predicted the dependent variable with a p value 
<0.200 on univariable analysis were considered in the multivari-
able analysis. We controlled for missing CEA and chemotherapy 
data in the regression models when applicable and found they 
were not significant except where noted.
All statistical tests were two-sided and p values <0.05 were 
considered significant. Statistical analyses were carried out using 
SPSS version 20 (IBM Corp., Armonk, NY, USA).
resUlTs
In our cohort, 36 patients achieved a CR (26.3%). One hundred 
and twenty-three patients underwent surgery following CRT, and 
15 patients were managed non-operatively. Of the patients who 
were managed operatively, 30 (24.5%) achieved a pCR.
Of the patients managed non-operatively, four were found 
to have metastatic disease immediately following completion of 
CRT. Four patients did not achieve a cCR, but did not undergo 
surgery due to poor performance status or patient preference, 
and were excluded from the survival analysis. The remaining 
six patients (40%) achieved a cCR, the median time to cCR 
among these patients was 80  days [interquartile range (IQR) 
40.3–261.5  days], and the median follow-up was 21.5  months 
(IQR 5.5–50.8 months).
Patient Population and characteristics
Demographic and clinical variables of the patients are reported 
in Table  1. The mean age of patients at diagnosis overall was 
57.9 ± 13.4 years with no significant difference between patients 
who achieved a CR and those who did not (p =  0.445). The 
37.7% of patients were female, and the gender distribution was 
similar between patient achieving a CR and those who did not 
(p = 0.531). Mean distance of the tumor from the anal verge was 
greater in the no CR group compared to the CR group (6.3 ± 3.5 
vs. 4.5 ± 3.5 cm, p = 0.020). Mean CEA at diagnosis was signifi-
cantly lower in patients achieving a CR than those who did not 
(3.1 ± 2.5 vs. 24.3 ± 80.5 μg/L, p = 0.024). CEA data were missing 
on 31 patients (22.5%); there was no difference in the proportion 
of missing data in the CR and no CR groups (p = 0.332).
Treatment characteristics
Chemoradiation characteristics are presented in Table  2. Four 
patients did not receive concurrent chemotherapy. Patients 
achieving a CR received a lower RT dose to the pelvis (4337 ± 559 
vs. 4473 ± 173 cGy, p = 0.030). The two groups were otherwise 
homogeneous in terms of their CRT regimens and received 
induction and consolidation (post-CRT) chemotherapy in simi-
lar proportions.
Operative management was similar in the CR and no CR groups; 
however, significantly more patients underwent APR in the CR 
group compared to the no CR group (36.7 vs. 15.1%, p = 0.016) 
(Table  3). One patient with a low-lying T2N0M0 rectal cancer 
underwent transanal excision and pathology revealed pT0Nx.
Predictors of complete response
There was no difference in patient age (p  =  0.465), gender 
(p = 0.691), distance of the tumor from the anal verge (p = 0.515), 
tumor size (p  =  0.473), differentiation (p  =  0.395), cT stage 
(p =  0.582), cN stage (p =  0.628), CEA level (p =  0.401), or 
neutrophil to lymphocyte ratio (NLR) level (p = 0.650) between 
pCR and cCR patients. pCR and cCR patients received similar 
RT doses (p =  0.485 for pelvic dose and p =  0.293 for boost 
dose), and concurrent chemotherapy (p =  0.089). While none 
of the operatively managed patients received induction or con-
solidation chemotherapy, one cCR patient received induction 
chemotherapy and three cCR patients received consolidation 
chemotherapy (p < 0.001). None of the 10 patients with mucinous 
adenocarcinoma achieved a CR.
On univariable analysis, tumor ≥3  cm from the anal verge, 
tumor size ≥3  cm, CEA ≥5 μg/L at diagnosis, clinically node-
positive disease at diagnosis, increased RT duration, RT dose to 
the pelvis, and interval from CRT to surgery <8 weeks predicted 
against CR. On multivariable analysis, CEA ≥5 μg/L at diagnosis 
(OR 0.190, 95% CI 0.037–0.971, p = 0.046), tumor size ≥3 cm 
(OR 0.123, 95% CI 0.020–0.745, p = 0.023), distance of tumor 
from the anal verge ≥3  cm (OR 0.091, 95% CI 0.013–0.613, 
p  =  0.014), clinically node-positive disease at diagnosis (OR 
0.201, 95% CI 0.045–0.895, p = 0.035), and interval from CRT 
to surgery ≥8 weeks (OR 5.267, 95% CI 1.068–25.961, p = 0.041) 
were independent predictors of CR (Table 4).
Oncologic Outcomes
The median follow-up time was 24.5  months (IQR 10.0–
49.3 months), and this was similar in the CR and no CR group 
(p = 0.936). At the time of this review, 123 patients were alive 
and 15 patients were deceased. Seven patients were lost to clinical 
follow-up by 1 year following treatment. In our population over-
all, mean OS was 106.8 months (95% CI 77.210–116.447 months) 
and 3-year OS was 90.0%.
In the pCR group, one patient failed locoregionally, and one 
patient failed both locoregionally and distantly. None of the cCR 
patients have recurred. Kaplan–Meier curves for LRC, DMFS, 
DFS, and OS are presented in Figure 1. Three-year DMFS (93.7 
vs. 63.7%, p = 0.016) and 3-year DFS (91.1 vs. 67.8%, p = 0.038) 
were longer among patients with a CR. While the CR group had 
longer 3-year LRC (96.6 vs. 81.3%, p = 0.103) and 3-year OS (97.2 
vs. 87.5%, p = 0.125), this did not reach statistical significance.
TaBle 1 | Baseline patient demographics and clinical characteristics.
Variables Total (n = l38) cr (n = 36) no cr (n = 102) p Value
Mean age ± SD (year) 57.9 ± 13.4 59.3 ± 12.3 57.4 ± 13.8 0.445
Female (%) 52 (37.7%) 12 (33.3%) 40 (39.2%) 0.531
Mean distance from anal verge ± SD (cm) 5.9 ± 3.6 4.5 ± 3.6 6.3 ± 3.5 0.020
Mean tumor size ± SD (cm) 5.4 ± 3.0 5.0 ± 3.9 5.6 ± 2.7 0.535
Differentiation (%) 0.989
 Well 8 (5.8%) 2 (5.6%) 6 (5.9%)
 Moderate 85 (61.6%) 20 (55.6%) 65 (63.7%)
 Poor 16 (11.6%) 4 (11.1%) 12 (11.8%)
 Unknown 29 (21.0%) 10 (27.8%) 19 (18.6%)
Histology (%) 0.121
 Adenocarcinoma 127 (92.0%) 36 (100%) 91 (89.2%)
 Mucinous adenocarcinoma 10 (7.2%) 0 10 (9.8%)
 Adenocarcinoma with neuroendocrine features 1 (0.7%) 0 1 (1.0%)
cT (%) 0.224
 1 3 (2.2%) 2 (5.6%) 1 (1.0%)
 2 16 (11.6%) 5 (13.9%) 11 (10.8%)
 3 108 (78.3%) 28 (77.8%) 80 (78.4%)
 4 8 (5.8%) 0 8 (7.8%)
 x 3 (2.2%) 1 (2.8%) 2 (2.0%)
cN (%) 0.135
 0 44 (31.9%) 17 (47.2%) 27 (26.5%)
 1 71 (51.4%) 15 (41.7%) 56 (54.9%)
 2 22 (15.9%) 4 (11.1%) 18 (17.6%)
 x 1 (0.7%) 0 1 (1.0%)
CEA
 Mean CEA ± SD (μg/L) 18.4 ± 68.9 3.l ± 2.5 24.3 ± 80.5 0.024
 CEA ≥ 5 μg/L (%) 45 (32.6%) 6 (16.7%) 39 (38.2%) 0.004
 Missing data 31 (22.5%) 6 (16.7%) 25 (24.5%) 0.332
Mean neutrophil count ± SD (cells/μL) 4.5 ± l.7 4.9 ± 2.3 4.4 ± l.5 0.252
Mean lymphocyte count ± SD (cells/μL) 1.8 ± 0.6 1.8 × 0.6 1.8 ± 0.7 0.993
Median NLR ± SD 3.0 ± 2.2 3.3 ± 3.2 2.9 ± l.7 0.389
NLR ≥5 at diagnosis (%) 13 (9.4%) 2 (5.6%) 11 (10.8%) 0.433
SD, standard deviation; CEA, carcinoembryonic antigen; NLR, neutrophil:lymphocyte ratio.
The p Values that are significant (p<0.05) are bolded.
TaBle 2 | characteristics of chemoradiation.
Variables Total (n = 138) cr (n = 36) no cr (n = 102) p Value
Mean time to CRT ± SD (days) 61.8 ± 82.3 53.2 ± 74.1 61.3 ± 85.3 0.903
Mean RT dose ± SD (cGy) 4994 ± 334 4942 ± 502 5012 ± 254 0.287
Mean RT dose to pelvis ± SD (cGy) 4439 ± 322 4337 ± 559 4473 ± 173 0.030
Mean boost to gross disease ± SD (cGy) 532 ± 211 530 ± 247 534 ± 199 0.931
Mean RT duration ± SD (days) 40.2 ± 6.2 39.0 ± 5.6 40.6 ± 6.3 0.171
RT interruption (%) 31 (22.5%) 7 (19.4%) 24 (23.5%) 0.614
Concurrent chemotherapy (%) 0.382
 5-FU or capecitabine 119 (86.2%) 33 (91.7%) 86 (90.5%)
 Oxaliplatin-containing regimena 8 (5.8%) 3 (8.3%) 5 (5.3%)
 None 4 (2.9%) 0 4 (4.2%)
 Missing data 7 (5.1%) 0 7 (6.7%)
Additional chemotherapy (%) 0.593
 Induction 7 (5.1%) 1 (2.8%) 6 (5.9%)
 Consolidation 8 (5.8%) 3 (8.3%) 5 (4.9%)
SD, standard deviation; CRT, chemoradiation; RT, radiation therapy; SD, standard deviation; 5-FU, 5 fluorouracil.
aChemotherapy regimen containing oxaliplatin plus 5-FU or capecitabine.
The p Values that are significant (p<0.05) are bolded.
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TaBle 4 | Predictors of complete response to chemoradiation.
Univariable regression Multivariable regression
covariables Or 95% ci p value Or 95% ci p Value
≥3 cm from anal verge 0.362 0.142–0.925 0.034 0.091 0.013–0.613 0.014
Tumor size ≥3 cm 0.269 0.079–0.918 0.036 0.123 0.020–0.745 0.023
CEA ≥5 μg/L at diagnosis 0.244 0.90–0.662 0.006 0.190 0.037–0.971 0.046
cN+ 0.408 0.185–0.898 0.026 0.201 0.045–0.895 0.035
RT duration (days) 0.953 0.887–1.025 0.197 – – NS
RT dose to pelvis (cGy) 0.999 0.998–1.000 0.078 – – NS
CRT to surgery interval ≥8 weeks 2.384 0.989–5.759 0.053 5.267 1.068–25.961 0.041
OR, odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen; RT, radiation therapy; CRT, chemoradiation.
The p Values that are significant (p<0.05) are bolded.
TaBle 3 | characteristics of surgical management.
Variables Total (n = 123) cr (n = 30) no cr (n = 93) p Value
CRT to surgery interval ≥8 weeks (%) 67 (54.4%) 21 (70.0%) 46 (49.5%) 0.059
Surgical procedure (%) 0.016
 LAR 96 (78.0%) 18 (60%) 78 (83.9%)
 APR 25 (20.3%) 11 (36.7%) 14 (15.1%)
 Transanal excision 1 (0.8%) 1 (3.3%) 0
 Proctectomy 1 (0.8%) 0 1 (1.1%)
Mean LNs resected ± SD (n) 17.9 ± 10.4 14.5 ± 7.4 19.0 ± 11.0 0.013
ypT (%) <0.001
 0 32 (26.0%) 30 (100%) 2 (2.2%)
 1 6 (4.9%) – 6 (6.5%)
 2 28 (22.8%) – 28 (30.1%)
 3 52 (42.3%) – 52 (55.9%)
 4 3 (2.4%) – 3 (3.2%)
 x 2 (1.6%) – 2 (2.2%)
ypN (%) <0.001
 0 78 (63.4%) 30 (100%) 48 (51.6%)
 1 28 (22.8%) – 28 (30.1%)
 2 16 (13.0%) – 16 (17.2%)
 x 1 (0.8%) – 1 (1.1%)
ypM+ (%) 4 (3.3%) – 4 (4.3%) 0.197
Positive margins (%) 6 (4.9%) – 6 (6.5%) 0.154
LVI (%) 25 (20.3%) – 25 (26.9%) 0.01
SD, standard deviation; CRT, chemoradiation; LAR, low anterior resection; APR, abdominoperineal resection; LN, lymph node; LVI lymphovascular invasion.
The p Values that are significant (p<0.05) are bolded.
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On multivariable analysis, concurrent chemotherapy 
(p =  0.022), metastatic disease at surgery (ypM+) (0.028), and 
number of lymph nodes resected (p =  0.001) were predictive 
of locoregional failure. Increased absolute lymphocyte count 
(p =  0.007), concurrent chemotherapy (p <  0.001), and ypM+ 
(p < 0.001) were predictive of distant metastasis. Consolidation 
chemotherapy was associated with increased chance of distant 
metastasis on univariable analysis (p < 0.001), but could not be 
included on multivariate analysis due to collinearity with ypM+. 
When consolidation chemotherapy was included in the multi-
variable model instead of ypM+, it was a significant predictor of 
distant metastasis (HR 5.330, 95% CI 1.524–18.639, p = 0.009). 
Male gender (p =  0.020), mucinous adenocarcinoma histology 
(p = 0.010), CEA ≥5 μg/L at diagnosis (p = 0.039), and presence 
of an unplanned treatment break (p = 0.043) were associated with 
disease recurrence (Table 5). When consolidation chemotherapy 
was considered in the multivariable model instead of ypM+, it 
was not a significant predictor of disease recurrence. Importantly, 
missing concurrent chemotherapy data were significant in the 
multivariable models for locoregional recurrence (p  <  0.001) 
and distant recurrence (p = 0.003) but not for disease recurrence.
DiscUssiOn
Several studies have assessed the ability of clinical and radio-
graphic data to accurately detect a cCR; however, there is evidence 
that these strategies miss many complete responders (11–15). In 
fact, a recent study found that 74% of patients with a pCR had a 
residual mucosal abnormality on gross examination (16). Given 
this, clinical and pathologic variables that are associated with a 
CR will likely continue to be valuable in risk-stratifying rectal 
cancer patients for the watch-and-wait strategy. We found CEA 
<5 μg/L at diagnosis, tumor size <3 cm, tumor distance <3 cm 
from the anal verge, clinically node-negative disease, and interval 
FigUre 1 | Kaplan–Meier curves of locoregional control, distant metastasis-free survival, disease-free survival, and overall survival for complete 
response (cr) patients (bold line) and no complete response (no cr) patients (dashed line). CR patients had longer distant metastasis-free survival and 
disease-free survival on log-rank test (p values shown in graphs).
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from the end of CRT to surgery ≥8 weeks to be predictive of CR 
following CRT for rectal cancer. Patients who achieved a CR had 
significantly longer DMFS and DFS. In addition, LRC and OS 
were longer among CR patients but this did not achieve statistical 
significance, likely due to the small sample size. While OS in the 
entire population was similar to nationally reported averages, OS 
among CR patients was much higher (17, 18). CR was not an 
independent predictor of LRC, DMFS, or DFS.
Few studies have assessed clinical or pathologic predictors of 
cCR. In their prospective trials of the watch-and-wait approach, 
Habr-Gama et  al. have found no clinical differences between 
complete clinical responders and non-complete responders (19) 
and no independent predictors of cCR (20). Several other small, 
single-institutional studies have aimed to identify predictors 
of pCR. As evidence suggests that cCR and pCR outcomes are 
equivalent, we believe that combining pCR and cCR data to assess 
for predictors of CR is a valid strategy to identify potential clinical 
predictors (7, 9, 21). Further, the similar distribution of clinical 
characteristics between the cCR and pCR groups in our cohort 
supports the validity of combining the two populations. We hope 
that our experience will contribute to our ability to accurately 
predict CR.
Morphologic characteristics of the tumor, including size, 
mobility, circumferentiality, ulceration, and distance of the tumor 
from the anal verge have all been identified as predictors of pCR 
(22–27). In our cohort, both increased tumor size and increased 
distance from the anal verge predicted against CR. As two other 
studies have also found decreasing tumor size to predict for CR, 
it is reasonable to consider this variable when risk-stratifying 
patients for the watch-and-wait approach (26, 27). Interestingly, 
Restivo et  al. found tumors >5  cm from the anal verge to be 
predictive of pCR (25). This conflicts with our own findings that 
more distal tumors predict CR. In our cohort, this association 
remained when non-operatively managed patients were excluded 
from the analysis (data not shown). While we reported similar 
median distance from the anal verge as Restivo et al., our IQR 
was wider and thus it is possible that very distal tumors are more 
susceptible to CRT. As distal rectal cancers are more amenable to 
clinical surveillance, more data are needed to understand whether 
distance from the anal verge is predictive of CRT response.
TaBle 5 | Univariable and multivariable analysis of long-term oncologic outcomes.
covariables Univariable regression Multivariable regression
hr 95% ci p value hr 95% ci p Value
locoregional failure
 cN+ 38.153 0.302–4824.220 0.140 – – NS
 Neutrophil count at diagnosis 1.244 0.929–1.666 0.142 – – NS
 Treatment break 3.286 1.102–9.800 0.033 – – NS
 Concurrent chemotherapy 0.128 0.016–1.018 0.052 0.081 0.009–0.698 0.022
 ypM+ 6.735 1.486–30.528 0.013 12.212 1.314–113.477 0.028
 LNs resected 1.045 1.007–1.085 0.021 1.066 1.026–1.107 0.001
 CR following CRT 0.215 0.028–1.655 0.140 – – NS
Distant failure
 Lymphocyte count at diagnosis (cells/μL) 0.506 0.262–0.978 0.043 0.275 0.108–0.700 0.007
 CEA ≥5 μg/L at diagnosis 2.846 1.101–7.357 0.031 – – NS
 Treatment break 0.2619 1.212–5.662 0.014 – – NS
 Total RT dose (cGy)a 1.001 0.999–1.004 0.168
 RT boost to gross disease (cGy) 1.001 1.000–1.003 0.068 – – NS
 Concurrent chemotherapy 0.114 0.034–0.384 <0.001 0.025 0.004–0.153 <0.001
 Induction chemotherapy 2.794 0.648–12.043 0.168 – – NS
 Consolidation chemotherapyb 3.750 1.292–10.888 <0.015
 ypM+ 9.531 3.206–28.332 <0.001 21.836 5.078–93.896 <0.001
Disease recurrence
 Male gender 0.427 0.200–0.028 0.028 0.337 0.135–0.840 0.020
 Mucinous adenocarcinoma 3.382 1.282–8.921 0.014 4.477 1.436–13.951 0.010
 CEA ≥5 μg/L at diagnosis 2.185 0.904–5.283 0.083 2.675 1.050–6.818 0.039
 Treatment break 2.408 1.125–5.155 0.024 2.696 1.030–7.057 0.043
 Total RT dosea (cGy) 1.001 0.999–1.003 0.172
 RT boost to gross disease (cGy) 1.001 1.000–1.003 0.070 – – NS
 Concurrent chemotherapy 0.169 0.040–0.716 0.016 – – NS
 Consolidation chemotherapyb 2.770 0.832–9.215 0.097
 ypN+ 2.217 0.992–4.851 0.052 – – NS
 ypM+ 6.031 1.781–20.420 0.004 – – NS
 CR following CRT 0.304 0.092–1.009 0.052 – – NS
HR, hazard ratio; CI, confidence interval; RL, reference level; CR, complete response; CRT, chemoradiation; RT, radialion therapy; CEA, carcinoembryonic antigen; LN, lymph node.
aNot included in multivariable analysis due to collinearity with RT to gross disease.
bNot included in multivariable model for distant recurrence due to collinearity with ypM+.
The p Values that are significant (p<0.05) are bolded.
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Carcinoembryonic antigen, currently used to monitor for 
disease recurrence in colorectal cancer, has been investigated as a 
biomarker for response to CRT. In agreement with our findings, 
many studies have found CEA level at the time of diagnosis to 
be associated with CR (24, 25, 27–32). Although 22.5% of CEA 
levels were missing, this was not significant when controlled for 
on regression analysis and our consistency with other studies sug-
gests this relationship is real. While we did not evaluate post-CRT 
CEA levels, this has also been found to be predictive of pCR in 
other studies (27, 30, 33). The reproducibility of these findings 
among so many populations suggests that this variable is a reliable 
predictor of sensitivity to CRT.
In agreement with our findings, clinical node positivity has 
been shown by two other retrospective studies to be indepen-
dently associated with decreased chance of achieving a CR (26, 
32). Given these findings, it is possible that clinical node positivity 
may be a marker for more aggressive disease that is less sensitive 
to local therapy. These patients may be less likely to benefit from 
non-operative management. Thus, especially careful patient selec-
tion for the watch-and-wait strategy is warranted for patients with 
stage III disease at this time. More studies are needed to clarify the 
appropriate role of non-operative management in patients with 
clinically node-positive disease at the time of diagnosis.
Similar to our study, Kalady et  al. found an interval of 
≥8 weeks from the end of CRT to surgery to be associated with 
improved pCR rates (34). In addition, a meta-analysis including 
3584 patients showed that an interval >6–8 weeks is associated 
with a 6% increase in pCR rate (35). These findings provide guid-
ance in determining the ideal time at which to evaluate patients 
for CRT response. As tumor killing with CRT is not immediate, 
an increased interval allows more patients who will eventually 
achieve a CR to be considered for non-operative management. 
Prospective studies of the watch-and-wait approach have evalu-
ated patients for response at variable intervals, ranging from 4 to 
10 weeks following CRT (7, 9, 10, 19–21). As evidence suggests 
that intervals ≥8 weeks may increase patients’ chances of rectal 
preservation, prospective studies are needed to determine the 
ideal time to evaluate for a CR.
Few studies have evaluated the import of RT treatment inter-
ruptions on achievement of a CR, one of the few modifiable factors 
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that may affect outcomes. Our findings are consistent with the 
two other retrospective studies that have evaluated this treatment 
variable and have found no association (27, 36). Nevertheless, we 
found unplanned treatment breaks to be associated with greater 
risk of disease recurrence. Similarly, one of the above studies 
found duration of RT ≥40 days to be borderline associated with 
DFS (HR 4.45, 95% CI 0.99–20.1, p = 0.052) (27). In light of the 
available data, care should be taken to minimize RT interruptions 
for rectal cancer patients.
The dearth of consistent and accurate clinical predictors of 
CR across multiple studies reveals a need for more precise prog-
nosticators. Our improving ability to classify tumors through 
genotyping and phenotyping holds great potential to enhance our 
ability to determine which patients are most likely to benefit from 
a watch-and-wait strategy (37). One study analyzed 47 primary 
tumors for 60 frequent mutations, and found that fewer patients 
with a mutation either pre- or post-CRT achieved a pCR com-
pared to patients with wild-type tumors (3.3 vs. 23.5%, p = 0.05) 
(27). In addition, several retrospective studies have found asso-
ciations between the NLR or circulating lymphocyte count and 
treatment response or long-term outcomes, suggesting a role of 
the immune system in determining sensitivity to CRT (38–41). In 
our study, we found no association between NLR and outcomes, 
but did find that increasing lymphocyte count predicted against 
distant failure. Although these peripheral markers are affected 
by a variety of inflammatory states and thus are not specific for 
CRT response, these findings hint at a role of the immune system 
in determining treatment response. In the future, tumor sam-
pling with in-depth genotyping and immunophenotyping may 
improve risk stratification and reveal novel strategies to improve 
chemo- and radiosensitivity.
Our study has several limitations inherent to its retrospective 
nature. Our population was relatively small, and thus our study 
may not have the statistical power to detect differences in survival 
between CR and non-CR patients. Nevertheless, most studies 
assessing predictors of CR are small and retrospective in nature, 
and we believe that our findings will add to the understanding 
of CRT response. In addition, our median follow-up interval of 
24.5 months is sub-optimal, limiting our ability to assess predic-
tors of survival. This, in combination with the sample size, may 
explain why we did not identify CR as an independent predictor 
of outcomes. Nevertheless, both pCR and cCR has been associ-
ated with improved long-term outcomes, and thus we believe 
that identifying predictors of CR is clinically relevant despite the 
negative findings of our study (2, 19). Also, the missing concur-
rent chemotherapy data on 5.1% of patients was significant on 
regression analysis of locoregional recurrence and disease recur-
rence, limiting interpretation of these models. Finally, a subset of 
patients managed non-operatively was not managed per a formal 
watch-and-wait protocol. While it is possible that some of these 
patients did not in fact achieve a cCR, none of them have recurred 
at the time of preparation of this manuscript, and thus we believe 
it is reasonable to include them in the cCR group.
cOnclUsiOn
In conclusion, we found higher CEA level at diagnosis, increased 
tumor size, increased distance from the anal verge, node-positive 
disease at diagnosis, and smaller interval from CRT to surgery 
to predict against CR to CRT. In our cohort, patients with a CR 
exhibited improved DMFS and DFS. These results are hypothesis 
generating and may aid in clinical decision making when consid-
ering patients for the watch-and-wait strategy. As this strategy is 
increasingly being adopted in clinical practice, larger prospective 
studies are needed to establish which clinicopathologic factors 
accurately predict CR.
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